Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib

NCT02627677 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.

NCT NCT02627677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02627677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
Lead sponsor
Ariad Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2015
Completion date
January 20, 2021
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase chronic myeloid leukemia